ZOGENIX, INC. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2012-12-10: Form 8-K; Period of report 2012-12-07; Description 8.01 Other Events; Details 8.01.
- 2012-11-26: Form 8-K; Period of report 2012-11-26; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2012-11-08: Form 8-K; Period of report 2012-11-08; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2012-11-02: Form 8-K; Period of report 2012-11-02; Description 1.01 Entry into a Material Definitive Agreement; Details 1.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2012-12-10 | 8-K | 2012-12-07 | 8.01 Other Events | 8.01 On December 7, 2012, Zogenix, Inc. (the “Company”) announced that the U.S. Food and Drug Administration’s (“FDA”) Anesthetic and Analgesic Drug Products Advisory Committee (“AADPAC”) voted 2-11 [with 1 abstention] against the approval of Zohydro ER™ (hydrocodone bitartrate extended-release capsules), an extended-release formulation of hydrocodone without acetaminophen, for the management of moderate-to-severe chronic pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time. | d451221d8k.htm |
| 2012-11-26 | 8-K | 2012-11-26 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On November 26, 2012, Zogenix, Inc. (“Zogenix” or the “Company”) announced the appointment of R. Scott Shively as Executive Vice President and Chief Commercial Officer, effective immediately. | d444217d8k.htm |
| 2012-11-08 | 8-K | 2012-11-08 | 2.02 Results of Operations and Financial Condition | 2.02 On November 8, 2012, Zogenix, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2012. | d434980d8k.htm |
| 2012-11-02 | 8-K | 2012-11-02 | 1.01 Entry into a Material Definitive Agreement | 1.01 On November 2, 2012, Zogenix, Inc. (“Zogenix” or the “Company”) and Alkermes Pharma Ireland Limited (“Alkermes”) entered into a commercial manufacturing and supply agreement for Zohydro ER finished commercial product (the “Supply Agreement”). | d432953d8k.htm |
| 2012-08-08 | 8-K | 2012-08-08 | 2.02 Results of Operations and Financial Condition | 2.02 On August 8, 2012, Zogenix, Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2012. | d393883d8k.htm |
| 2012-08-01 | 8-K | 2012-07-30 | 1.02 Termination of a Material Definitive Agreement | 1.02 On July 30, 2012, Zogenix, Inc. (the “Company”) repaid in full the entire $19.5 million of outstanding principal and interest under its Second Amended and Restated Loan and Security Agreement among Oxford Finance LLC, successor in interest to Oxford Finance Corporation, and Silicon Valley Bank (the “Loan Agreement”). | d388846d8k.htm |
| 2012-07-25 | 8-K/A | 2012-07-24 | 9.01 Financial Statements and Exhibits | d385718d8ka.htm | |
| 2012-07-24 | 8-K | 2012-07-24 | 8.01 Other Events | 8.01 On July 24, 2012, Zogenix, Inc. (the “Company” or “Zogenix”) entered into an underwriting agreement (the “Underwriting Agreement”) with Stifel, Nicolaus & Company, Incorporated and Wells Fargo Securities, LLC, as representatives of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale of 32,500,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (“Common Stock”), and warrants to purchase 14,625,000 shares of Common Stock (the “Warrants”). | d384151d8k.htm |
| 2012-07-23 | 8-K | 2012-07-23 | 2.02 Results of Operations and Financial Condition | 2.02 Zogenix, Inc.’s (the “Company” or “Zogenix”) cash and cash equivalents were approximately $22.0 million as of June 30, 2012. | d383428d8k.htm |
| 2012-07-16 | 8-K | 2012-07-13 | 8.01 Other Events | 8.01 On July 16, 2012, Zogenix, Inc. (the “Company” or “Zogenix”) announced that the U.S. Food and Drug Administration (the “FDA”) has accepted for review the New Drug Application (“NDA”) for Zohydro™ (hydrocodone bitartrate extended-release capsules), the Company’s lead investigational product candidate for the treatment of moderate to severe chronic pain. | d380874d8k.htm |
| 2012-07-12 | 8-K | 2012-07-12 | 8.01 Other Events | 8.01 On July 12, 2012, Zogenix, Inc. (the “Company” or “Zogenix”) announced that it initiated its first investigational new drug (“IND”) clinical trial for Relday™, which is a product candidate based on a combination of the Company’s DosePro® needle-free, subcutaneous drug delivery system plus a proprietary, subcutaneous once-monthly formulation of risperidone for treating schizophrenia. | d379886d8k.htm |
| 2012-06-07 | 8-K | 2012-06-06 | 1.01 Entry into a Material Definitive Agreement | 1.01 On June 6, 2012, Zogenix, Inc. (“Zogenix”) and Mallinckrodt LLC (“Mallinckrodt”) entered into a co-promotion agreement. | d366488d8k.htm |
| 2012-06-06 | 8-K | 2012-06-06 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 Zogenix, Inc. (the “Company”) held its annual meeting of stockholders on June 6, 2012. | d364068d8k.htm |
| 2012-05-30 | 8-K | 2012-05-30 | 8.01 Other Events | 8.01 On May 30, 2012, Zogenix, Inc. (the “Company” or “Zogenix”) submitted an investigational new drug (“IND”) application to the U.S. Food & Drug Administration (the “FDA”) for Relday™, which is a combination of the Company’s DosePro® needle-free, subcutaneous drug delivery system plus a proprietary, subcutaneous once-monthly formulation of risperidone for treating schizophrenia. | d360672d8k.htm |
| 2012-05-14 | 8-K | 2012-05-14 | 2.02 Results of Operations and Financial Condition | 2.02 On May 14, 2012, Zogenix, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2012. | d352945d8k.htm |
| 2012-05-02 | 8-K | 2012-05-02 | 8.01 Other Events | 8.01 On May 2, 2012, Zogenix, Inc. (the “Company”) submitted a New Drug Application (“NDA”) to the U.S. Food and Drug Administration for Zohydro™ (hydrocodone bitartrate extended-release capsules), the Company’s lead investigational product candidate for the treatment of chronic pain. | d342345d8k.htm |
| 2012-04-17 | 8-K | 2012-04-12 | 1.01 Entry into a Material Definitive Agreement | 1.01 On April 12, 2012, Zogenix, Inc. (the “Company”) entered into an Office Sublease (the “Sublease”) with Relational Investors, LLC to lease approximately 13,124 rentable square feet of office space from Relational Investors on the 6th floor of the building located at 12400 High Bluff Drive, Suite 650, San Diego, California 92130. | d336067d8k.htm |
| 2012-03-30 | 8-K | 2012-03-29 | 1.01 Entry into a Material Definitive Agreement | 1.01 On March 29, 2012, Zogenix, Inc. (the “Company” or “Zogenix”) entered into a Co-Marketing and Option Agreement (the “Co-Marketing Agreement”) with Battelle Memorial Institute (“Battelle”). | d324761d8k.htm |
| 2012-03-08 | 8-K | 2012-03-08 | 2.02 Results of Operations and Financial Condition | 2.02 On March 8, 2012, Zogenix, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and full-year ended December 31, 2011. | d313106d8k.htm |
| 2012-01-09 | 8-K | 2012-01-09 | 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure | 2.02 During the week of January 9, 2012, representatives of Zogenix, Inc. will be attending meetings with investors, analysts and others in connection with the JP Morgan Healthcare conference in San Francisco, California. 7.01 The slides attached as Exhibit 99.1 to this Current Report on Form 8-K are incorporated herein by reference. | d279320d8k.htm |